Semax

Batch #190624Batch # 190624
Report #Report #
Tested atPENDINGTested at PENDING
Size: 10mg
Money Back Guarantee Money Back Guarantee
Satisfaction Guarantee Satisfaction Guarantee
Easy Returns Easy Returns
Secure Ordering Secure Ordering
2-Day Shipping 2-Day Shipping
Third Party Tested Third Party Tested
Batch & Lot Tracking Batch & Lot Tracking

RESEARCH USE ONLY
These compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

About Semax

Product Specifications

Lyophilized Powder in 3ml vial.

Application

Research peptide with potential in cognitive enhancement studies

Appearance

Solid, white powder in 3mL glass ampule

Chemical Formula

C37H51N9O10S

PubChem CID
CAS Number

80714-61-0

Molecular Weight

854.99 g/mol

Synonyms

Semax, Phenylacetyl-L-prolylglycyl-L-proline ethyl ester

Storage

Store at ≤6°C, sealed, away from heat, light, and moisture.

1. Clinical Overview 

Semax is a synthetic peptide of adrenocorticotropic hormone (ACTH 4–10) developed in Russia.The drug has a number of nootropic and neuroprotective properties. It has also been clinically proven to improve cognitive performance, stroke rehabilitation, stress adaptation, etc.

 

2. Human Clinical Findings  

Researchers studied how the peptide Semax affected gene activity in stroke-affected animals compared to those that did not receive it, at 3 and 24 hours after a stroke. They found that Semax mainly boosted the activity of genes related to the immune system. Three hours after the stroke, it influenced genes that control immune cell activity, and by 24 hours, this effect became much stronger. More than half of all the genes changed by Semax were linked to immune responses, especially those responsible for producing immunoglobulins and chemokines.

Semax also altered the activity of genes related to the vascular system. Three hours after the stroke, 24 vascular genes were affected, and 12 were affected after 24 hours. These genes are involved in important processes such as blood vessel growth, cell movement, blood formation, and the development of new vessels.

Another randomized controlled trial was conducted. The study included 110 patients with acute ischemic stroke. Thirty patients were administered Semax, a synthetic of ACTG-4-10; the other 80 patients received standard treatment and formed the control group. The recovery assessment was performed with clinical scales, EEG mapping, and evoked potentials testing. 

The results indicated a significantly earlier recovery after adding Semax and its beneficial effect on general brain function and motor activity. The most effective daily dose was 12 mg for moderate stage and 18 mg for severe stroke. All the calculations were provided over 5-10 days.

 

3. Clinical Overview 

Furthermore, Semax boosts the expression of brain-derived neurotrophic factor and other molecules of protection for neurons. They promote the survival of neurons and synaptic plasticity; thus, learning and plasticity improves. Semax also balances the work of neurotransmitters involved in mood and the body’s response to stress. 

Additionally, by improving oxygen utilization in brain tissue and preventing oxidative damage to neurons, Semax stabilizes the brain during stress, hypoxia, or neurodegenerative processes.

 

4. Safety & Considerations  

Across human trials, Semax has shown an excellent safety profile with no reported toxicity or dependence. Most side effects, if any, are mild and temporary (such as nasal irritation). However, larger international studies are still needed to confirm long-term safety and efficacy outside of Russian populations.

Semax has a good safety profile in all human trials; no toxicity or dependence was reported. In some cases, mild, short-lived side effects such as sore throat and dryness and irritation in the nasal cavity are possible.

References

  1. Ashmarin IP, et al. Neuroprotective and cognitive effects of Semax in ischemic stroke patients. Human Physiology. 1998.

  2. Volkov IM, et al. Effect of Semax on attention and memory under stress in healthy volunteers. Neuroscience and Behavioral Physiology. 1999.

  3. Kolesnikova TO, et al. Semax therapy in children with ADHD: clinical and neurochemical outcomes. Neurosci Behav Physiol. 2007.

 

You ask,
we answer.